Company: XOMAP
Filing Date: 2025-09-17
Form Type: SC TO-T/A
Source: 0001193125-25-205563
Chunk: 1

Company: XOMA Royalty Corp
Filing Date: 2025-09-17
Form: SC TO-T/A
Chunk 1
---
1 (this “”) amends and supplements the
Tender Offer Statement on Schedule TO originally filed under cover of Schedule TO on August 18, 2025 (together with any subsequent amendments and supplements thereto, the “”), by XOMA Royalty Corporation, a Nevada
corporation (“”), and XRA 4 Corp., a Delaware corporation and a wholly owned subsidiary of Parent (“” and together with Parent, “”). This Amendment relates to the
offer (the “”) to purchase all of the issued and outstanding shares of common stock, par value $0.0001 per share (“”), of HilleVax, Inc., a Delaware corporation (“”), for a
price per Share of (i) $1.95 (the “”), which Cash Amount is based on an estimated amount of Closing Net Cash (as defined in the Merger Agreement defined below) as of August 4, 2025, equal to $102,950,000, payable
without interest, and (ii) one non-transferable contractual contingent value right (“”) for each Share, which shall represent the right to receive potential payments, in cash,
described in, and subject to and in accordance with the terms and conditions of, the CVR Agreement, without interest (such amount, the “,” and together with the Cash Amount, the “”), all
upon the terms and subject to the conditions described in the Offer to Purchase, dated August 18, 2025 (together with any amendments or supplements thereto, the “”), and in the related Letter of Transmittal,
copies of which are attached to the Schedule TO as exhibits (a)(1)(A) and (a)(1)(B), respectively. The Offer is being made pursuant to the Agreement and Plan of Merger, dated as of August 4, 2025 (together with any amendments or supplements
thereto, the “”), among HilleVax and Purchasers, a copy of which is filed as Exhibit (d)(1) to the Schedule TO and incorporated herein by reference with respect to Items 4 through 11 of this Amendment.

Except as otherwise set forth in this Amendment, all terms of the Offer and all other disclosures set forth in the Schedule TO and the
Exhibits thereto remain unchanged and are hereby expressly incorporated into this Amendment by reference. This Amendment should be read together with the Schedule TO. Capitalized terms used and not otherwise defined in this Amendment shall have the
meanings assigned to